Hasil Pencarian  ::  Simpan CSV :: Kembali

"Penelitian ini bertujuan untuk membandingkan efektivitas biaya penggunaan sediaan D10-CaGluconas dan D5-1/4NS. Disain penelitian adalah kohort retrospektif pada pasien neonatus penderita Respiratory Distress Syndrome (RDS) dengan berat badan normal di RSU Kambang Jambi. Penelitian dilaksanakan pada kurun waktu September 2014-Juni 2015. Subyek penelitian terbagi dalam dua kelompok yaitu yang menggunakan D10-CaGluconas 40 pasien dan D5-1/4NS 43 pasien. Efektivitas dinilai dari perubahan hasil pemeriksaan fisik pasien yaitu rata - rata berat badan (28,48 gram/hari), kadar glukosa darah sewaktu (26,73 mg/dL), respiratory rate (-12,35 x/menit), frekuensi nadi (-10,98 x/menit), dan temperatur tubuh (0,013oC) pada sediaan D10-CaGluconas. Rata - rata efektivitas berat badan (23,49 gram/hari), kadar glukosa darah sewaktu (26,42 mg/dL), respiratory rate (-7,77 x/menit), frekuensi nadi (-8,07 x/menit), dan temperatur tubuh (0,012oC) pada sediaan D5-1/4NS. Rata - rata biaya langsung medis sediaan D10-CaGluconas adalah Rp. 458.290 dan D5-1/4NS adalah Rp. 408.347. Nilai ACER total biaya langsung medis sediaan D10-CaGluconas adalah Rp. 35.207.467, nilai ACER sediaan D5-1/4NS adalah Rp. 33.958.602. Nilai ICER biaya langsung medis sediaan D5-1/4NS terhadap sediaan D10-Ca.gluconas tiap efektivitas kenaikan berat badan adalah Rp. 10.009, kadar glukosa darah sewaktu adalah Rp. 161.107, respiratory rate adalah Rp. 10.905, frekuensi nadi adalah Rp. 17.163 dan temperatur tubuh adalah Rp. 49.943.000. Nilai rata - rata ICER total biaya langsung medis sediaan B terhadap sediaan A adalah Rp. 10.017.210. Sediaan parenteral nutrisi D10-CaGluconas lebih costeffective dibandingkan dengan sediaan D5-1/4NS.

---

This study aimed to compare the cost-effectiveness of the use of D10-CaGluconate and D5-1/4NS preparations. The design was a retrospective cohort study in neonatal Respiratory Distress Syndrome (RDS ) patients with normal weights in RSU Kambang Jambi. The research was conducted during the period September 2014 to June 2015. The research subjects were divided into two group, the use of D10-CaGluconate was 40 patients and D5-1/4NS was 43 patients . Effectiveness were seen from the changes of the patients physical examination results, on averages weights (28.48 grams/day), blood glucose levels (26.73 mg/dL), respiratory rates (-12.35 x/min), pulse rates (-10.98x/min), and the body temperature (0.013°C ) in D10-CaGluconate preparations. The average effectiveness of weight (23.49 grams/day), blood glucose levels (26.42 mg/dL), respiratory rates (-7.77 x/min ), pulse rates (-8.07 x/min), and the body temperatures (0.012°C) in D5-1/4NS preparations. The Average direct medical costs of D10- CaGluconate and D5-1/4NS were Rp. 458,290 and Rp. 408,347. The ACER values of total direct medical costs of D10-CaGluconate preparation were Rp. 35,207,467, while D5-1/4NS was Rp. 33,958,602. The ICER values of the direct medical costs of the D5-1/4NS preparations of D10-CaGluconas on each effectiveness of weights were Rp. 10,009, blood glucose levels were Rp. 161,107, respiratory rates were Rp. 10,905, pulse rates were Rp. 17,163, and the body temperature was Rp. 49,943,000. The averages ICER values of the direct medical costs of the D5-1/4NS preparations of D10-CaGluconate were Rp. 10,017,210. The parenteral nutrition preparations of D10-CaGluconate are more cost-effective compared to the D5-1/4NS."

"COVID-19 merupakan penyakit infeksi baru yang menimbulkan beban ekonomi pada layanan kesehatan dan negara. Oleh karena itu perlu dilakukan analisis biaya terapi pasien COVID-19 sebagai langkah awal dalam mengetahui beban ekonomi yang diakibatkan oleh COVID-19. Penelitian ini menggunakan desain cross-sectional dengan pengambilan data secara retrospektif, dilihat dari perspektif rumah sakit. Subjek penelitian adalah pasien COVID-19 derajat sedang yang dirawat inap di Rumah Sakit Universitas Indonesia pada bulan Agustus - Desember 2020. Hasil penelitian menunjukkan bahwa sampel penelitian didominasi oleh laki-laki (58,9%) dan kategori usia 26-45 tahun (44,9%). Komorbiditas yang paling banyak yaitu hipertensi (30,0%). Total biaya COVID-19 yang diperoleh sebesar Rp30.499.984,00 ± 8.274.857 per pasien dengan biaya pada pasien dengan komorbiditas sebesar Rp30.916.570,00 ± 8.913.798 dan biaya pada pasien tanpa komorbiditas sebesar Rp29.903.508 ± 7.322.026. Hasil ini dapat dijadikan sebagai masukan bagi rumah sakit untuk menentukan clinical pathway COVID-19.

---

COVID-19 is a new infectious disease with a heavy economic burden for healthcare facilities and the country. This study was conducted to analyze the cost of treatment of direct medical cost based on a hospital perspective. This study used a cross-sectional design with retrospective data collection. The subjects of this study were COVID-19 inpatients of a moderate degree at University of Indonesia Hospital in August – December 2020. The results showed the subjects were dominated by men (58,9%) and the age category of 26-45 years old (44,9%). The comorbidity with the highest prevalence was hypertension (30,0%). The total cost of treatment was Rp30.499.984,00 ± 8.274.857 per patient. Patients with comorbidities had a total cost of Rp30.916.570,00 ± 8.913.798 while patients without comorbidity had a total cost of Rp29.903.508 ± 7.322.026. This result can be used as a recommendation for hospital in establishing a clinical pathway for COVID-19.

"